COLLEGIUM PHARMACEUTICAL INC (COLL) Fundamental Analysis & Valuation

NASDAQ:COLL • US19459J1043

Current stock price

33.25 USD
+0.02 (+0.06%)
At close:
33.08 USD
-0.17 (-0.51%)
After Hours:

This COLL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. COLL Profitability Analysis

1.1 Basic Checks

  • In the past year COLL was profitable.
  • In the past year COLL had a positive cash flow from operations.
  • COLL had positive earnings in 4 of the past 5 years.
  • In the past 5 years COLL always reported a positive cash flow from operatings.
COLL Yearly Net Income VS EBIT VS OCF VS FCFCOLL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • The Return On Assets of COLL (3.79%) is better than 84.46% of its industry peers.
  • With an excellent Return On Equity value of 20.84%, COLL belongs to the best of the industry, outperforming 91.19% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 10.19%, COLL belongs to the top of the industry, outperforming 89.12% of the companies in the same industry.
  • COLL had an Average Return On Invested Capital over the past 3 years of 12.68%. This is in line with the industry average of 13.06%.
Industry RankSector Rank
ROA 3.79%
ROE 20.84%
ROIC 10.19%
ROA(3y)4.06%
ROA(5y)4.07%
ROE(3y)25.24%
ROE(5y)19.62%
ROIC(3y)12.68%
ROIC(5y)9.74%
COLL Yearly ROA, ROE, ROICCOLL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • The Profit Margin of COLL (8.05%) is better than 83.94% of its industry peers.
  • COLL's Profit Margin has been stable in the last couple of years.
  • Looking at the Operating Margin, with a value of 23.01%, COLL belongs to the top of the industry, outperforming 89.64% of the companies in the same industry.
  • In the last couple of years the Operating Margin of COLL has grown nicely.
  • COLL has a Gross Margin of 59.35%. This is in the better half of the industry: COLL outperforms 69.43% of its industry peers.
  • COLL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.01%
PM (TTM) 8.05%
GM 59.35%
OM growth 3Y15.44%
OM growth 5Y4.89%
PM growth 3YN/A
PM growth 5Y-1.41%
GM growth 3Y8.71%
GM growth 5Y0.46%
COLL Yearly Profit, Operating, Gross MarginsCOLL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. COLL Health Analysis

2.1 Basic Checks

  • COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for COLL has been increased compared to 1 year ago.
  • Compared to 5 years ago, COLL has less shares outstanding
  • The debt/assets ratio for COLL has been reduced compared to a year ago.
COLL Yearly Shares OutstandingCOLL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
COLL Yearly Total Debt VS Total AssetsCOLL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • COLL has an Altman-Z score of 1.39. This is a bad value and indicates that COLL is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of COLL (1.39) is comparable to the rest of the industry.
  • The Debt to FCF ratio of COLL is 2.47, which is a good value as it means it would take COLL, 2.47 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.47, COLL belongs to the top of the industry, outperforming 92.75% of the companies in the same industry.
  • A Debt/Equity ratio of 2.59 is on the high side and indicates that COLL has dependencies on debt financing.
  • COLL has a Debt to Equity ratio of 2.59. This is in the lower half of the industry: COLL underperforms 78.76% of its industry peers.
  • Although COLL's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 2.47
Altman-Z 1.39
ROIC/WACC1.09
WACC9.35%
COLL Yearly LT Debt VS Equity VS FCFCOLL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • COLL has a Current Ratio of 1.57. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.57, COLL is not doing good in the industry: 68.91% of the companies in the same industry are doing better.
  • COLL has a Quick Ratio of 1.48. This is a normal value and indicates that COLL is financially healthy and should not expect problems in meeting its short term obligations.
  • COLL has a Quick ratio of 1.48. This is in the lower half of the industry: COLL underperforms 63.21% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.48
COLL Yearly Current Assets VS Current LiabilitesCOLL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. COLL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.66% over the past year.
  • COLL shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 57.90% yearly.
  • Looking at the last year, COLL shows a very strong growth in Revenue. The Revenue has grown by 23.62%.
  • COLL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.28% yearly.
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
Revenue 1Y (TTM)23.62%
Revenue growth 3Y18.94%
Revenue growth 5Y20.28%
Sales Q2Q%12.92%

3.2 Future

  • Based on estimates for the next years, COLL will show a decrease in Earnings Per Share. The EPS will decrease by -2.39% on average per year.
  • Based on estimates for the next years, COLL will show a small growth in Revenue. The Revenue will grow by 1.28% on average per year.
EPS Next Y2.08%
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%
EPS Next 5Y-2.39%
Revenue Next Year3.76%
Revenue Next 2Y-3.4%
Revenue Next 3Y-2.41%
Revenue Next 5Y1.28%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
COLL Yearly Revenue VS EstimatesCOLL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
COLL Yearly EPS VS EstimatesCOLL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 6

More info and screens

Find the best growth stocksShow best growing peers

8

4. COLL Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 4.46, the valuation of COLL can be described as very cheap.
  • 96.37% of the companies in the same industry are more expensive than COLL, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of COLL to the average of the S&P500 Index (25.61), we can say COLL is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 4.37, the valuation of COLL can be described as very cheap.
  • 95.34% of the companies in the same industry are more expensive than COLL, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 22.79. COLL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 4.46
Fwd PE 4.37
COLL Price Earnings VS Forward Price EarningsCOLL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COLL is valued cheaper than 97.93% of the companies in the same industry.
  • COLL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. COLL is cheaper than 97.41% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.22
EV/EBITDA 3.26
COLL Per share dataCOLL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of COLL may justify a higher PE ratio.
  • COLL's earnings are expected to decrease with -12.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)2.14
PEG (5Y)0.08
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. COLL Dividend Analysis

5.1 Amount

  • COLL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COLL Fundamentals: All Metrics, Ratios and Statistics

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (3/25/2026, 8:19:05 PM)

After market: 33.08 -0.17 (-0.51%)

33.25

+0.02 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners122.15%
Inst Owner Change1.07%
Ins Owners2%
Ins Owner Change1.19%
Market Cap1.06B
Revenue(TTM)780.57M
Net Income(TTM)62.87M
Analysts81.67
Price Target54.74 (64.63%)
Short Float %14.85%
Short Ratio9.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.08%
Min EPS beat(2)-14.08%
Max EPS beat(2)7.92%
EPS beat(4)3
Avg EPS beat(4)-0.58%
Min EPS beat(4)-14.08%
Max EPS beat(4)7.92%
EPS beat(8)6
Avg EPS beat(8)8.51%
EPS beat(12)9
Avg EPS beat(12)-12.74%
EPS beat(16)10
Avg EPS beat(16)-13.58%
Revenue beat(2)1
Avg Revenue beat(2)3.07%
Min Revenue beat(2)-2.39%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.34%
Min Revenue beat(4)-2.39%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.58%
Revenue beat(12)5
Avg Revenue beat(12)-0.05%
Revenue beat(16)8
Avg Revenue beat(16)0.3%
PT rev (1m)0.94%
PT rev (3m)10.27%
EPS NQ rev (1m)0.28%
EPS NQ rev (3m)0.7%
EPS NY rev (1m)-6.01%
EPS NY rev (3m)-6.83%
Revenue NQ rev (1m)-2.86%
Revenue NQ rev (3m)-2.47%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)-0.04%
Valuation
Industry RankSector Rank
PE 4.46
Fwd PE 4.37
P/S 1.35
P/FCF 3.22
P/OCF 3.21
P/B 3.5
P/tB N/A
EV/EBITDA 3.26
EPS(TTM)7.46
EY22.44%
EPS(NY)7.62
Fwd EY22.9%
FCF(TTM)10.32
FCFY31.03%
OCF(TTM)10.37
OCFY31.2%
SpS24.58
BVpS9.5
TBVpS-16.18
PEG (NY)2.14
PEG (5Y)0.08
Graham Number39.94
Profitability
Industry RankSector Rank
ROA 3.79%
ROE 20.84%
ROCE 14.76%
ROIC 10.19%
ROICexc 14.94%
ROICexgc 844.11%
OM 23.01%
PM (TTM) 8.05%
GM 59.35%
FCFM 41.97%
ROA(3y)4.06%
ROA(5y)4.07%
ROE(3y)25.24%
ROE(5y)19.62%
ROIC(3y)12.68%
ROIC(5y)9.74%
ROICexc(3y)19.7%
ROICexc(5y)15.04%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)18.36%
ROCE(5y)14.11%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y20.9%
ROICexc growth 5Y-2.38%
OM growth 3Y15.44%
OM growth 5Y4.89%
PM growth 3YN/A
PM growth 5Y-1.41%
GM growth 3Y8.71%
GM growth 5Y0.46%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 2.59
Debt/FCF 2.47
Debt/EBITDA 1.92
Cap/Depr 0.77%
Cap/Sales 0.22%
Interest Coverage 2.61
Cash Conversion 81.17%
Profit Quality 521.05%
Current Ratio 1.57
Quick Ratio 1.48
Altman-Z 1.39
F-Score7
WACC9.35%
ROIC/WACC1.09
Cap/Depr(3y)0.69%
Cap/Depr(5y)86.46%
Cap/Sales(3y)0.19%
Cap/Sales(5y)24.98%
Profit Quality(3y)461.5%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.66%
EPS 3Y137.06%
EPS 5Y57.9%
EPS Q2Q%15.25%
EPS Next Y2.08%
EPS Next 2Y-5.87%
EPS Next 3Y-12.23%
EPS Next 5Y-2.39%
Revenue 1Y (TTM)23.62%
Revenue growth 3Y18.94%
Revenue growth 5Y20.28%
Sales Q2Q%12.92%
Revenue Next Year3.76%
Revenue Next 2Y-3.4%
Revenue Next 3Y-2.41%
Revenue Next 5Y1.28%
EBIT growth 1Y5.73%
EBIT growth 3Y37.3%
EBIT growth 5Y26.16%
EBIT Next Year47.71%
EBIT Next 3Y9.31%
EBIT Next 5Y7.76%
FCF growth 1Y61.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.66%
OCF growth 3Y38.41%
OCF growth 5Y28.53%

COLLEGIUM PHARMACEUTICAL INC / COLL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

ChartMill assigns a fundamental rating of 6 / 10 to COLL.


What is the valuation status for COLL stock?

ChartMill assigns a valuation rating of 8 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.


What is the profitability of COLL stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.


Can you provide the financial health for COLL stock?

The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.